- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCEULLULAR CARCINOMA (MORPHEUS-NEO HCC)
This study is looking into new combinations of medicines for people with a type of liver cancer that can be removed with surgery. It aims to see how well these new treatments work before surgery and if they are safe.
For: Hepatocellular Carcinoma (Morpheus-Neo HCC)Austria · Spain · Germany - Active not recruitingPHASE1, PHASE2
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This study is testing a new discovery drug called RO7247669 for advanced cancers. It aims to find the safest and most effective dose, and see if it can shrink certain tumours like melanoma, lung, and oesophageal cancer. The drug works by boosting the body's own immune system to fight cancer.
For: Solid Tumors · Metastatic Melanoma · Non-small Cell Lung CancerDenmark · Georgia · Israel - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants with Previously Untreated Unresectable or Metastatic Melanoma
This study is testing a new medicine called RO7247669 for advanced skin cancer (melanoma) that has spread or can't be removed by surgery. It's an early-stage trial looking at how safe the medicine is and if it can help slow down or stop the cancer from growing.
For: Unresectable or Metastatic MelanomaPoland · Greece · Slovakia